The COVID-19 Treatment Guidelines were developed to provide clinicians with guidance on caring for
patients with COVID-19. Because clinical information about the optimal management of COVID-19
is evolving quickly, these Guidelines are updated frequently to reflect newly published data and other
authorita...
Pavlick, Anna C;
Ariyan, Charlotte E;
Buchbinder, Elizabeth I;
Davar, Diwakar;
Gibney, Geoffrey T;
Hamid, Omid;
Hieken, Tina J;
Izar, Benjamin;
Johnson, Douglas B;
Kulkarni, Rajan P;
Luke, Jason J;
Mitchell, Tara C;
Mooradian, Meghan J;
Rubin, Krista M;
Salama, April K. S;
Shirai, Keisuke;
Taube, Janis M;
Tawbi, Hussein A;
Tolley, J Keith;
Valdueza, Caressa;
Weiss, Sarah A;
Wong, Michael K;
Sullivan, Ryan J.
Since the first approval for immune checkpoint inhibitors
(ICIs) for the treatment of cutaneous melanoma more than
a decade ago, immunotherapy has completely transformed
the treatment landscape of this chemotherapy-resistant
disease. Combination regimens including ICIs directed
against programmed cell de...
Brandsma, D;
Curigliano, G;
Furtner, J;
Le Rhun, E;
Minniti, G;
Peters, S;
Preusser, M;
Rudà, R;
Schadendorf, D;
Seoane, J;
Tonn, J. C;
van den Bent, M;
Weller, M;
Wick, W;
Wesseling, P.
These joint European Association of Neuro-Oncology (EANO)–European Society for Medical Oncology (ESMO) recommendations for the diagnosis and treatment of leptomeningeal metastasis (LM) from solid tumours provide an update of the first joint EANO–ESMO guideline1 and complement the EANO–ESMO guidelin...
NICE is unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. This is because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission....
Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Commercial arrangement
There is a commercial arrangement for nivolumab. NHS organisations can get...
